Streetbeat News

Partnerships

VLCN

Volcon, an electric vehicle manufacturer, has demonstrated its products to key Department of Defense (DoD) staff and has entered a funded operational energy program. The company's stock symbol is VLCN.

Portfolio Pulse from Benzinga Newsdesk

July 05, 2023 | 1:18 pm

MRNA

Moderna has signed a deal with Chinese officials to research, develop, and manufacture mRNA medicines in China. The deal, which could be worth around $1 billion, is Moderna's first agreement with China and the first to involve developing mRNA medicines overall, not just Covid shots. The drugs developed will be exclusively for the Chinese people and will not be exported. This comes despite rising tensions between the U.S. and China.

Portfolio Pulse from Benzinga Newsdesk

July 05, 2023 | 1:16 pm

PL

AI-Powered Impact Observatory has announced a partnership with Planet Labs. The partnership will leverage AI-powered analytics to monitor land cover and land use on top of Planet's high-frequency, medium-resolution, and high-resolution satellite data.

Portfolio Pulse from Benzinga Newsdesk

July 05, 2023 | 1:05 pm

CCCC

C4 Therapeutics Inc's stock is surging after the FDA cleared its investigational new drug (IND) application for CFT8919, a BiDAC degrader developed to target EGFR L858R in non-small cell lung cancer patients. This is C4's fourth IND clearance from its proprietary TORPEDO platform. In May, C4 entered into an exclusive licensing agreement with Betta Pharmaceuticals for the development and commercialization of CFT8919 in China.

Portfolio Pulse from Adam Eckert

July 05, 2023 | 1:04 pm

ORA

Ormat Technologies, Inc (NYSE:ORA) and San Diego Community Power (SDCP) have signed a power purchase agreement for the Arrowleaf Solar and Storage Facility. The facility, located in Imperial County, California, will provide SDCP with sustainable electricity at predictable rates for customers under a 20-year contract. The solar component of the project will contribute 42 MW of clean energy to the grid, enough to power approximately 31,500 homes. Operations are expected to commence in the first half of 2025.

Portfolio Pulse from Happy Mohamed

July 05, 2023 | 12:53 pm

CYTO

Altamira Therapeutics has announced a collaboration with Heqet Therapeutics to test nanoparticles based on Altamira's OligoPhore delivery platform for cardiac regeneration. The aim is to regenerate damaged heart tissue.

Portfolio Pulse from Benzinga Newsdesk

July 05, 2023 | 12:48 pm

NNDM

Nano Dimension Ltd. (NNDM) has announced progress in commercializing its in-house DeepCube Group's industrial AI services. The company has signed an agreement with a multinational electronics company to use DeepCube's deep learning-based AI technology and is in advanced discussions with several other companies. The technology is used to improve the efficacy of processes, which can lead to significant financial benefits. The company's CEO, Yoav Stern, expressed satisfaction with the market's response to the technology.

Portfolio Pulse from Happy Mohamed

July 05, 2023 | 12:34 pm

CLPR

Clipper Realty Inc. (NYSE:CLPR) has reached a 40-year regulatory agreement with the New York City Department of Housing Preservation and Development for its 2,500-unit Flatbush Gardens property. The agreement includes a full abatement of real estate taxes, maintenance of current rents, and a commitment to make capital improvements over a three-year period. The deal is expected to be accretive to the company's AFFO and FFO.

Portfolio Pulse from Happy Mohamed

July 05, 2023 | 12:33 pm

CPX

FSLR

Capital Power Corporation has secured its first order for approximately 1 gigawatt of ultra-low carbon thin film solar modules from First Solar, Inc. The modules will be delivered between 2026 and 2028, supporting Capital Power's growing development portfolio. First Solar's modules are known for their quality, durability, reliability, design, and environmental performance. Capital Power is committed to net zero by 2045 and is focusing on solar energy growth across North America. First Solar is investing approximately $1.3 billion in expanding its US manufacturing footprint.

Portfolio Pulse from Happy Mohamed

July 05, 2023 | 12:31 pm

PFE

Pfizer Inc and Samsung Biologics have signed two agreements for the long-term manufacturing of Pfizer's multiproduct biosimilar portfolio, worth $897 million. The deals include a $193 million deal and a $704 million deal, making it Samsung Biologics' most significant single contract since its inception in 2011. Samsung Biologics will provide Pfizer with additional capacity for large-scale manufacturing for a multiproduct biosimilar portfolio covering oncology, inflammation, and immunology. The deals will last through 2029.

Portfolio Pulse from Vandana Singh

July 05, 2023 | 12:24 pm